FDA accepts Lymphoseek NDA, and critic responds (Weekend Rounds)

A review of life science current events reported by MedCity News this week.

Neoprobe: FDA accepts Lymphoseek New Drug Application. FDA acceptance of the Lymphoseek NDA is an important milestone for the Dublin, Ohio, company and provides vindication over a once-vocal hedge fund manager critic who raised questions about the design of the drug’s clinical trials.

Neoprobe: Hedge fund critic still predicts FDA rejection of drug. After remaining silent on Neoprobe (NYSE Amex:NEOP) the last few months, the cancer diagnostics company’s most outspoken critic and short seller has found himself back in the spotlight after the FDA accepted for review a drug application from the company.

Cleveland Clinic’s wellness chief Roizen’s latest venture: Enforcer eCoaching. Entrepreneurial Cleveland Clinic wellness guru Dr. Michael Roizen is aiming to further cash in on the wellness wave by starting another company, an online wellness coaching startup called Enforcer eCoaching.

Some ideas on how to get PhDs to act like innovative entrepreneurs. How do we make scientists better entrepreneurs? Make it worthwhile, get crazy and think young.

St. Jude’s stock shines as the world awaits Quadra. St. Jude Medical (NYSE:STJ) reported strong earnings and buyers responded, pushing the company’s stock price up 4.3 percent to $38.95. While profits were up notably, the focus is on St. Jude’s robust’ albeit delayed’ pipeline of products. Primarily, analysts and shareholders are eager for the delivery of Quadra, a slightly delayed cardiac therapy device that is expected to be a major win for the company while cutting into the market share of the Boston Scientific.